Keryx Pharmaceuticals Private Limited
About Keryx Pharmaceuticals Private Limited
Data last updated:
Keryx Pharmaceuticals Private Limited is a private limited company based in Mohali, Punjab, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 05 March 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U24232PB2007PTC030937. Its GSTIN is 01AADCK1283H1ZY (Jammu and Kashmir).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Ajay Mengi and Renu Mengi.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 488 Industrial Area Phase 9, Mohali, Punjab, India – 144003.
As per the financials filed for FY 2025, the company reported a revenue of ₹30.46 Lakh, a growth of 33% compared to the previous year. For the same year it recorded a net profit of ₹2,891 (net margin 0.1%) and EBITDA of ₹1.6 Lakh (EBITDA margin 5.3%). Revenue has grown at a compounded annual rate (CAGR) of 10% over three years and 2% over five years.
As per MCA filings, the company has open charges of ₹40 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Keryx Pharmaceuticals Private Limited's registered office is in Mohali, Punjab. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Social Media
- Registered Address488 Industrial Area Phase 9, Mohali, Punjab, India – 144003
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of Keryx Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Keryx Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Keryx Pharmaceuticals Private Limited, buy the company report.
Financials of Keryx Pharmaceuticals Private Limited
FY 2025 filings availableKeryx Pharmaceuticals Private Limited reported revenue of ₹30.46 Lakh (up 33% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 2% over five years, including 33% growth in the latest year. EBITDA fell 28% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.6 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2,891 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.3% | ||||
| Net Profit Margin | 0.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Keryx Pharmaceuticals Private Limited, buy the company report.
Board of directors of Keryx Pharmaceuticals Private Limited
Keryx Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ajay Mengi | Director | 05 Mar 2007 | 19 Years 7 Months | Current |
| Renu Mengi | Director | 19 Mar 2011 | 15 Years 7 Months | Current |
Peer comparison
Keryx Pharmaceuticals Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| NRXN Pharmaceuticals Private Limited | ₹30.68 Lakh (FY 2024) | 2.0% | Bareilly, Uttar Pradesh, India | |||
| Accipere Pharmaceuticals Private Limited | ₹30.61 Lakh (FY 2025) | 0.0% | Kollam, Kerala, India | |||
| Macnis Pharmaceuticals Private Limited | ₹30.55 Lakh (FY 2023) | 27.0% | Delhi, India | |||
| Keryx Pharmaceuticals Private Limitedthis company | ₹30.46 Lakh (FY 2025) | ₹2,891 | 0.1% | 33.0% | Mohali, Punjab, India | |
| Ackrose Pharmaceuticals Private Limited | ₹30.44 Lakh (FY 2025) | -35.0% | Delhi, India | |||
| Bioclinical Pharmaceuticals Private Limited | ₹30.41 Lakh (FY 2022) | 47.0% | Pune, Maharashtra, India | |||
| Maxelon Pharmaceuticals Private Limited | ₹30.23 Lakh (FY 2025) | 5.0% | Naini, Uttar Pradesh, India | |||
| Thebes Pharmaceuticals Private Limited | ₹30.2 Lakh (FY 2025) | 58.0% | New Delhi, Delhi, India |
To see the full peer comparison of Keryx Pharmaceuticals Private Limited, buy the company report.
Auditor
Keryx Pharmaceuticals Private Limited is audited by Rakesh Ganesh & Associates for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Rakesh Ganesh & Associates | FY 2017 | 020917N |
Shareholding
The shareholding of Keryx Pharmaceuticals Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Keryx Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 23 Feb 2016 | 100055725 | Others | ₹40 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Keryx Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Keryx Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Keryx Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 01AADCK1283H1ZY | Jammu and Kashmir | Active | 08 Jul 2017 |
To see the full GST registrations and return filing status of Keryx Pharmaceuticals Private Limited, buy the company report.
Recent activity
Keryx Pharmaceuticals Private Limited has 3 board changes on record since 2007: 2 appointments and 1 cessation. The latest: Sanjeev Singh Bagal ceased to be Director on 21 Mar 2011.
Frequently asked questions
Keryx Pharmaceuticals is an active private limited company based in Mohali, Punjab, India. The company works in wholesale, within the trading industry. It was incorporated on 05 March 2007 (19+ years old) and is registered under CIN U24232PB2007PTC030937.
Keryx Pharmaceuticals has 2 current directors:
- Ajay Mengi - Director
- Renu Mengi - Director
The latest financial statements of Keryx Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Keryx Pharmaceuticals is 01AADCK1283H1ZY, registered in Jammu and Kashmir.
The CIN (Corporate Identification Number) of Keryx Pharmaceuticals is U24232PB2007PTC030937. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Keryx Pharmaceuticals was incorporated on 05 March 2007, making it 19+ years old. It is registered with the Registrar of Companies, Chandigarh.
The peers of Keryx Pharmaceuticals by revenue are NRXN Pharmaceuticals Private Limited, Accipere Pharmaceuticals Private Limited, Macnis Pharmaceuticals Private Limited, Ackrose Pharmaceuticals Private Limited, Bioclinical Pharmaceuticals Private Limited and 2 more, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Sanjeev Singh Bagal ceased to be Director on 21 Mar 2011. Renu Mengi was appointed as Director on 19 Mar 2011. Ajay Mengi was appointed as Director on 05 Mar 2007.
The registered office of Keryx Pharmaceuticals is at 488 Industrial Area Phase 9, Mohali, Punjab, India – 144003.
Keryx Pharmaceuticals operates in the trading industry, in the wholesale segment.
Keryx Pharmaceuticals has open charges of ₹40 Lakh and no satisfied charges on record as per latest MCA filings.